Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Tildrakizumab |
Synonyms | |
Therapy Description |
Ilumya (tildrakizumab) is a monoclonal antibody that binds to the p19 subunit of IL-23 and prevents interaction with the IL-23 receptor, potentially leading to decreased release of proinflammatory cytokines (PMID: 31548750). Ilumya (tildrakizumab) is FDA approved for use in patients with moderate-to-severe plaque psoriasis (FDA.gov). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Tildrakizumab | Ilumya | MK-3222 | Ilumya (tildrakizumab) is a monoclonal antibody that binds to the p19 subunit of IL-23 and prevents interaction with the IL-23 receptor, potentially leading to decreased release of proinflammatory cytokines (PMID: 31548750). Ilumya (tildrakizumab) is FDA approved for use in patients with moderate-to-severe plaque psoriasis (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|